## **ICMJE DISCLOSURE FORM**

Date:			3/12/2023		
Your Name:			JOANA FERRER FÀBREGA		
Manuscript Title:			Resection vs transplantation for hepatocellular carcinoma: a never ending challenge		
Manuscript Number (if known):		(nown):	Click or tap here to enter text.		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the mar indicate a bias. If you are in doubt The author's relationships/activitie epidemiology of hypertension, you that medication is not mentioned in the content of the content			ated" means any relation with for-profit or no nuscript. Disclosure represents a commitme t about whether to list a relationship/activity es/interests should be defined broadly. For e u should declare all relationships with manuf in the manuscript.	/interest, it is preferable that you do so.	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.			Click the tab key to add additional rows.	
			Time frame: past 36 month	s	
2	Grants or contracts from any entity (if not indicated in item #1 above).				
3	Royalties or licenses				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Consultancy fees from Astrazeneca	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ Lecture fees from Bayer and AstraZeneca	
6	Payment for expert testimony		
7	Support for attending meetings and/or travel		
8	Patents planned, issued or pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	□ I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

## **ICMJE DISCLOSURE FORM**

Date:			3/12/2023		
Your Name:			JORDI BRUIX		
Manuscript Title:			Resection vs transplantation for hepatocellular carcinoma: a never ending challenge		
Mar	nuscript Number (if	known):	Click or tap here to enter text.		
In the interest of transparency, we content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub."  The author's relationships/activiti epidemiology of hypertension, yo that medication is not mentioned.			nted" means any relation with for-profit or nuscript. Disclosure represents a commitre tabout whether to list a relationship/actives/interests should be defined broadly. For u should declare all relationships with mar in the manuscript.	ties/interests listed below that are related to the not-for-profit third parties whose interests may be nent to transparency and does not necessarily ty/interest, it is preferable that you do so.  r example, if your manuscript pertains to the ufacturers of antihypertensive medication, even if without time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planni	ng of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.			Click the tab key to add additional rows.	
			Time frame: past 36 mor	ths	
2	Grants or contracts from any entity (if not indicated in item #1 above).	is fund	ed grant support from CIBERehd which ed by the Instituto de Salud Carlos III. ional grants from Bayer		
3	Royalties or licenses				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Consultancy from Arqule, Bayer, Novartis, BM Gilead, Bio-Alliance, Roche, AbbVie, Merck, Sin Quirem, Adaptimmune, Lilly.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ Lecture fees from Bayer, BTG-Biocompatibles, T	Terumo, Roche, Sirtex, and Ipsen.
6	Payment for expert testimony		
7	Support for attending meetings and/or travel		
8	Patents planned, issued or pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		
13	Other financial or non-financial interests		
Please place an "X" next to the following statement to indicate your agreement:			
$[\boxtimes]$	oximes I certify that I have answered every question and have not altered the wording of any of the questions on this form.		